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Abstract
Introduction: Treatment with various biological agents in disease states such as rheumatoid arthritis has been
associated with multiple side effects. Whereas many of these are frequently reported in the literature,
hypoglycemia, a possible side effect of tumor necrosis factor-alpha inhibitors, may be underpublicized.
Case presentation: We report nine cases of non-diabetic Caucasian women who were between 29 and 68 years
of age and who developed low glucose readings after treatment with tumor necrosis factor-alpha inhibitors. We
provide a more detailed discussion of existing evidence of the role of tumor necrosis factor-alpha in the
pathogenesis of inflammation and its impact on glycemic equilibrium.
Conclusions: Physicians using tumor necrosis factor-alpha inhibitors in the treatment of various rheumatic and
other autoimmune diseases should be aware of the potential for the development of glycemic disturbance in
these patients. A further role of tumor necrosis factor-alpha inhibitors in the glycemic equilibrium warrants larger
controlled trials in patients with and those without a history of diabetes.
Introduction
Treatment with a biologic agent is useful for controlling
inflammatory disease states, such as rheumatoid arthritis
(RA), when disease-modifying anti-rheumatic drugs
(DMARDs) are not enough to fully control their activ-
ities [1]. Tumor necrosis factor-alpha (TNF-a) is cate-
gorized as a pro-inflammatory cytokine. It is thought
that this molecule is crucial in the initiation and conti-
nuation of inflammation in many rheumatic diseases,
including RA, psoriatic arthritis, ankylosing spondylitis,
and many others. Currently available TNF-a inhibitors
(etanercept, infliximab, adalimumab, certolizumab pegol,
and golimumab) aim to block pro-inflammatory actions
of this cytokine [2]. Their effectiveness to finally control
disease activities in various rheumatic diseases has been
proven in many randomized controlled studies [3-5].
However, TNF-a inhibitors entail a plethora of con-
cerns associated with their use. Some of the potential
side effects and complications include increased risk of
infusion reactions, life-threatening and opportunistic
infections (tuberculosis and fungal and other atypical
infections), malignancy, and existing concerns associated
with their use during pregnancy [2].
Interestingly, TNF-a i n h i b i t o r sm a ya l s op l a yar o l ei n
glycemic control since the TNF-a molecule is known to
affect glucose homeostasis. Outcomes affecting glycemic
control may be an underpublicized side effect in the lit-
erature. The evidence linking inflammation and diabetes
mellitus (DM) dates back more than a century. Studies in
mice showed a positive correlation between TNF-a
quantity and insulin resistance [6]. Additionally, other
studies have been confirmed in humans, in both those
with and those without diabetes mellitus type II (DM II)
[7]. Furthermore, insulin sensitivity was noted to improve
in patients with prolonged infliximab treatment [8]. In
this paper, we present nine patients who developed low
glucose readings after treatment with TNF-a inhibitors.
Case presentations
Table 1 includes detailed information regarding each of
the nine patients presented in our paper.
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Patient Diagnosis TNF-a
inhibitor
DMARD Age in
years,
BMI
Sex, race Episodes of
low glucose
readings
Venous
glucose
value, mg/
dL
Total duration
on TNF-a
inhibitor
Time before
development of
hypoglycemia
History
of
diabetes?
Family
history of
diabetes?
History of
gestational
diabetes?
1 RA Infliximab,
etanercept
Hydroxychloroquine 68, 22.0 Female,
Caucasian
2 67, 68 13 months
(infliximab),
10 months
(abatacept)
6 months, 10
months
No No No
2 RA, SLE,
CREST
syndrome
Infliximab Hydroxychloroquine,
MTX
54, 32.4 Female,
Caucasian
1 66 13 months
(infliximab)
8 months No Yes No
3 RA Infliximab Leflunomide 62, 22.1 Female,
Caucasian
1 60 24 months
(infliximab)
4 months No No No
4 RA, SpA Adalimumab Hydroxychloroquine 29, 18.3 Female,
Caucasian
1 67 3 months
(adalimumab)
3 months No No No
5 RA, FMS Certolizumab,
infliximab
Leflunomide 35, 19.3 Female,
Caucasian
2 69, 63 11 months
(abatacept),
14 months
(infliximab)
2 months,
3 months
No No No
6 RA, SLE,
CREST
syndrome
Adalimumab,
certolizumab,
infliximab
Leflunomide 55, 24.5 Female,
Caucasian
4 63, 62, 62, 68 17 months
(adalimumab),
17 months
(certolizumab)
4 months, 14
months, 15 months,
6 months
No No No
7 RA, vWD Adalimumab,
golimumab
MTX 30, 19.6 Female,
Caucasian
3 68, 58 11 months
(adalimumab),
3 months
(golimumab)
6 months, 1 month No No No
8 RA, SpA,
FMS
Adalimumab None 47, 21.4 Female,
Caucasian
1 54 11 months
(adalimumab)
2 months No No No
9 RA, FMS Infliximab Hydroxychloroquine 65, 19.8 Female,
Caucasian
1 64 24 months
(infliximab)
5 months No No No
BMI: body mass index; CREST: calcinosis, Raynaud syndrome, esophageal dysmotility, sclerodactyly, and telangiectasia; DMARD: disease-modifying anti-rheumatoid drug; FMS: fibromyalgia syndrome; MTX:
methotrexate; RA: rheumatoid arthritis; SLE: systemic lupus erythematosus; SpA: spondyloarthropathy; TNF-a: tumor necrosis factor-alpha; vWD: von Willebrand disease.
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6In Case 1, a 68-year-old Caucasian woman with a his-
tory of RA was initially treated with hydroxychloro-
quine. Since her disease activity was not adequately
controlled, additional treatment with TNF inhibitor
infliximab at 3 mg/kg intravenously was initiated. She
developed an episode of low blood glucose (a venous
glucose level of 67 mg/dL) six months after starting
treatment. Her infliximab was discontinued because of
ineffectiveness, and treatment with another biologic
agent, etanercept, at 50 mg subcutaneously weekly was
started. Subsequently, she developed another episode of
low blood glucose, of 68 mg/dL, 10 months after initiat-
ing treatment. So, overall, she developed two episodes of
low blood glucose readings: one of 67 mg/dL and the
other of 68 mg/dL. She was not symptomatic.
In Case 2, 54-year-old Caucasian woman had a history
of RA, systemic lupus erythematosus (SLE), CREST (cal-
cinosis, Raynaud syndrome, esophageal dysmotility,
sclerodactyly, and telangiectasia) syndrome, and a family
h i s t o r yo fD Mt y p eI I .S h ew a st r e a t e dw i t hh y d r o x y -
chloroquine and methotrexate. Owing to uncontrolled
disease activity, TNF-a inhibitor infliximab was added.
She developed one episode of low blood glucose reading
of 66 mg/dL 8 months after starting treatment with
infliximab. She was not symptomatic.
In Case 3, A 62-year-old Caucasian woman had a his-
tory of RA along with chronic anemia. Her RA was initi-
ally treated with leflunomide. Owing to uncontrolled
disease activity, TNF-a inhibitor infliximab at 3 mg/kg
intravenously was added to her treatment regimen. She
developed one episode of low blood glucose reading of
60 mg/dL four months after starting infliximab. She was
not symptomatic.
In Case 4, a 29-year-old Caucasian woman had a his-
tory of RA and seronegative spondyloarthropathy (SpA).
She was treated with hydroxychloroquine, and then,
owing to uncontrolled disease activity, TNF-a inhibitor
adalimumab at 40 mg subcutaneously was added. She
experienced one episode of low blood glucose reading
with a value of 67 mg/dL three months after starting
adalimumab. She was not symptomatic.
In case 5, a 45-year-old Caucasian woman with a his-
tory of RA and fibromyalgia syndrome (FMS) was initi-
ally treated with leflunomide. Subsequently, TNF-a
inhibitor certolizumab at 200 mg subcutaneously every
four weeks was added to her treatment regimen. She
had an episode of low blood glucose reading with a
value of 69 mg/dL two months after starting certolizu-
mab. Owing to intolerance, she was switched to another
TNF-a inhibitor, infliximab, at 3 mg/kg intravenously.
After three months, another bout of low blood glucose
reading, with a value of 63 mg/dL, occurred. So she
developed two episodes of low blood glucose readings:
one of 69 mg/dL after certolizumab and another, of 63
mg/dL, after infliximab. She was not symptomatic.
In case 6, a 55-year-old Caucasian woman with a his-
tory of RA, SLE, and CREST syndrome was treated with
leflunomide at the beginning, and then after her disease
activity was not controlled, TNF-a inhibitor adalimu-
mab at 40 mg subcutaneously was added. She developed
three episodes of low blood glucose readings of 63, 62,
a n d6 2m g / d Lf o u r ,1 4 ,a n d1 5m o n t h s ,r e s p e c t i v e l y ,
after starting adalimumab. Secondary to intolerance,
another anti-TNF inhibitor, certolizumab, was started.
Another episode of low blood glucose reading, of 68
mg/dL, developed six months after starting certolizu-
mab. So she developed three low blood glucose readings
of 63, 62, and 62 mg/dL, respectively, after initiation
treatment with adalimumab, and then another episode
of low blood glucose reading, of 68 mg/dL, after certoli-
zumab. She was not symptomatic.
In case 7, a 30-year-old Caucasian woman with a his-
tory of von Willebrand disease and RA was initially trea-
ted with methotraxate. After uncontrolled disease
activity, treatment with TNF-a inhibitor adalimumab at
40 mg subcutaneously was initiated. She developed one
episode of low blood glucose reading with a value of 68
mg/dL six months after starting adalimumab. Secondary
to intolerance, she was switched to golimumab at 50 mg
subcutaneously. Then, one month after starting golimu-
mab, another episode of low blood glucose reading was
recorded at 58 mg/dL. So she had one episode of low
blood glucose level of 68 mg/dL after adalimumab and
then another episode of low blood glucose reading, of
58 mg/dL, after golimumab. She was not symptomatic.
In case 8, a 47-year-old Caucasian woman had a his-
tory of SpA, FMS, and RA. Since her disease activity
was not well controlled, TNF-a inhibitor adalimumab at
40 mg subcutaneously every two weeks was initiated.
Subsequently, patient developed one episode of low glu-
cose reading of 54 mg/dL 2 months after starting adali-
mumab. She was not symptomatic.
In case 9, a 65-year-old Caucasian woman had a his-
tory of RA and FMS. Initially, she was treated with
hydroxychloroquine. After uncontrolled disease activity,
TNF-a inhibitor infliximab at 3 mg/kg intravenously
was started. She developed an episode of low blood glu-
cose level of 64 mg/dL five months after starting inflixi-
mab. She was not symptomatic.
Discussion
Biologic agents in the category of TNF-a inhibitors,
including etanercept, infliximab, adalimumab, certolizu-
mab pegol, and golimumab, have proven efficacious in
controlling disease activity of various rheumatic and
autoimmune diseases, including RA, psoriatic arthritis,
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against the TNF-a molecule [9].
In this paper, nine patients treated with TNF-a inhibi-
tors developed low blood glucose levels. Six of them
were treated with infliximab, five with adalimumab, two
with certolizumab pegol, and one with golimumab. The
average time of developing hypoglycemia after initiating
TNF-a inhibitor was 4.3 months; the shortest time was
one month, and the longest time was six months. The
level of hypoglycemia ranged from 54 to 69 mg/dL. All
of the patients treated were Caucasian women ranging
from 29 to 68 years of age. Only one patient treated had
a family history of DM type II (case 2), but none of the
patients had a personal history of DM type I or type II.
All of the recordings of blood glucose levels were done
retrospectively for approximately two hours in a post-
prandial state.
The body mass index (BMI) in our patients ranged
from 18.3 to 32.4, and the average was 22.15 (normal
weight). One patient had a BMI of 18.3, placing her in
the underweight category. Another patient had a BMI of
32.4, placing her in the obese category. The majority of
the BMIs were within normal weight category and
included the following values: 22.0, 22.1, 19.3, 24.5, 19.6,
21.4, and 19.8. It is known that higher BMI is associated
with increased risk for developing diabetes type II along
with cardiovascular disease such as coronary artery dis-
ease and high blood pressure. However, most of our
patients who developed low blood glucose readings had
BMIs within the normal weight category. This finding
suggests that the impact of TNF-a inhibitors on glycemic
equilibrium might be independent of BMI measurement.
While all nine patients had at least one bout of a low
blood glucose reading, four patients (cases 1, 5, 6, and
7) developed more than one episode of hypoglycemia
after initiating TNF-a inhibitor treatment. Case 1 was a
patient who had RA and who developed one episode of
a low blood glucose reading after treatment with inflixi-
mab and another low blood glucose reading after treat-
ment with etanercept. Case 5 was a patient who had RA
and who developed low blood glucose readings after
treatment with certolizumab and then after treatment
with infliximab. Case 5 was a patient who had RA and
who developed a low blood glucose reading while being
treated with certolizumab pegol and another low blood
glucose reading after switching to infliximab. Case 6 was
a patient who had RA, SLE, and CREST syndrome and
who had the highest incidence of low blood glucose
readings during this observational case series. Three epi-
sodes of low blood glucose readings occurred while she
was on adalimumab, and one episode occurred while
she was on certolizumab pegol. Case 7 had one episode
of low blood glucose reading while she was on adalimu-
mab and another episode while she was on golimumab.
The literature describes episodes of hypoglycemia
occurring in those with pre-existing diabetes and con-
current use of TNF-a inhibitors. Boulton and Borne
[10] report the case of a 55-year-old woman who had a
history of type I diabetes and RA and who developed
several episodes of hypoglycemia within three weeks
after initiating etanercept and subsequently within a 24-
hour period of starting adalimumab. Moreover, in
another case, a 54-year-old woman who had RA and
type II diabetes experienced periods of severe hypoglyce-
mia hours after receiving etanercept injections [11].
Farrokhi and colleagues [12] describe the case of a 59-
year-old woman who had psoriasis and type II diabetes
and who experienced symptomatic episodes of hypogly-
cemia of between 50 to 68 mg/dL six weeks after receiv-
ing etanercept injections. This patient exhibited an
unexpected improvement in glycemic control shortly
after beginning etanercept treatment, despite only mini-
mal change in body weight. Also, a decline of hemoglo-
bin A1C of 2.8% along with a significant decrease of
medication requirement for glycemic control was found
in this patient within nine months of treatment with
etanercept. This finding pointed to a salutary effect on
glucose metabolism [12]. In a similar case, a 51-year-old
woman who had type II diabetes and who was hospita-
lized with erythrodermic psoriasis experienced hypogly-
cemia of as low as 27 mg/dL and convulsions after only
seven hours of initiating etanercept, and insulin therapy
was discontinued to maintain normal glycemic control
[13].
Cheung and Bryer-Ash [14] describe a case of a 72-
year-old man who had a history of type II DM and
chronic plaque psoriasis and who developed hypoglyce-
mic events of 60 mg/dL or less a few times a week one
month after treatment with etanercept. His insulin dose
was progressively decreased and then completely discon-
tinued at 16 months of treatment with etanercept, and
instead he was treated only with oral anti-diabetic
agents. He no longer experienced episodes of hypoglyce-
mia, and at the end of 20 months of treatment with eta-
nercept, his BMI remained unchanged whereas his
fasting blood sugar levels improved [14].
In a small pilot study of 18 patients (11 males and
seven females), pediatric patients who had newly diag-
nosed type 1 diabetes and who were treated with etaner-
cept had lower A1C and increased endogenous insulin
production, suggesting preservation of beta-cell function.
From baseline to week 24, insulin doses decreased 18%
in the etanercept group but increased 23% in the pla-
cebo group [15].
So far, the only reported cases of hypoglycemia have
occurred in individuals who were treated with TNF-a
inhibitors and who had a known history of diabetes. In
our paper, the presentation is quite unusual since all
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readings after treatment with a TNF-a inhibitor did not
have an underlying history of diabetes. All of our
patients were women, whereas cases presented above
described both men and women. Whereas all of our
cases were asymptomatic, pointing to a more biochem-
ical hypoglycemia, all other reported cases with hypogly-
cemia occurred in diabetic patients who were treated
with TNF-a inhibitors and who were symptomatic. It is
possible that TNF inhibitors magnify the clinical effects
of hypoglycemia in patients with already-treated dia-
betes. Additionally, whereas the mean time before devel-
opment of low blood glucose readings observed in our
nine cases was 4.2 months, some instances describe epi-
sodes of hypoglycemia occurring within a few hours of
TNF inhibitor therapy in patients with pre-existing
diabetes.
Our study is a series of cases and aims to serve as a
guide for further investigations. However, it carries
some limitations. Mainly, it is not a randomized con-
trolled study. The recordings of low blood glucose levels
were done retrospectively. Additionally, there might be
inadequate exclusion of all other possible causes of low
blood glucose readings. Lastly, the threshold for low
blood glucose levels used here (< 70 mg/dL) is consid-
ered to be higher than the one used in current classic
criteria for hypoglycemia, which consists of serum glu-
cose levels of less than 50 to 55 mg/dL and, preferably,
documentation of Whipple triad for hypoglycemia (low
blood glucose concentration measured with a precise
method, presence of symptoms consistent with hypogly-
cemia, and symptom alleviation upon correction of
blood glucose) [16]. Thus, it may be undermining the
clinical significance of such low levels of glucose. How-
ever, a threshold of blood glucose level of less than 70
mg/dL is often used in anti-diabetic trials to monitor
any adverse effects. Also, the neuroendocrine responses
begin at an arterial plasma glucose concentration of less
than approximately 70 mg/dL [16].
On a more molecular level, the TNF-a molecule
appears to inhibit the insulin-mediated uptake of glu-
c o s ei na d i p o s et i s s u ev i aam e c h a n i s mo fd o w n r e g u l a t -
ing the GLUT-4 receptor. This could lead to a state of
insulin resistance [11]. It is possible that, in the patient
population presented here, the action of the TNF-a
inhibitors brought about increased insulin sensitivity
because of the blockade of TNF-a in adipose tissue [17].
H e n c e ,t h i sc o u l db eap r o p o s e dm e c h a n i s mf o rt h e
development of low blood glucose readings observed in
our cases.
Hotamisligil and colleagues [18] demonstrated that
TNF-a induced serine phosphorylation of insulin recep-
tor substrate 1 (IRS-1), which in turn caused the serine
phosphorylation of the insulin receptor. This prevented
the normal tyrosine phosphorylation of the insulin
receptor and thus interfered with insulin signal trans-
duction. Interleukin-6 and TNF-a have recently been
shown [19,20] to induce SOCS-3, a protein that was
thought to interfere with cytokine signal transduction
but that is now also known to interfere with tyrosine
phosphorylation of the insulin receptor and IRS-1 and
to cause ubiquitination and proteosomal degradation of
IRS-1 [21]. This, in turn, reduces the activation of Akt
(protein kinase B), which normally causes the transloca-
tion of the insulin-responsive glucose transporter Glut-4
to the plasma membrane. This also induces the phos-
phorylation of the enzyme nitric oxide synthase and its
activation to generate nitric oxide [22]. A newly
described protein, TRB3, has also been shown to inter-
fere with the activation of Akt and thus to interfere with
the action of insulin [23].
The evidence linking inflammation and DM dates
back more than a century. Overproduction of TNF-a
has been found in obesity, atherosclerosis, insulin resis-
tance, and type II DM [6]. Also, it was found that inhi-
bition of TNF-a resulted in the improvement of
peripheral uptake of glucose in response to insulin in
obese mice [6].
One report showed that chronic treatment with inflix-
imab for either RA or psoriatic arthritis brought about a
substantial improvement in insulin sensitivity [8]. In the
same study, one patient with type II diabetes actually
reverted to a state in which glucose tolerance was
impaired and insulin therapy ceased. Another study
pointed out that glycemic control could improve after
24 months of etanercept therapy [15]. It stands to rea-
son, therefore, that the TNF-a inhibitors used to treat
RA could indeed induce a state of hypoglycemia with
chronic use.
Conclusions
In our paper, we presented nine cases of non-diabetic
patients who developed episodes of low blood glucose
readings after treatment with TNF-a inhibitors. The
proposed mechanism might involve induction of
increased insulin sensitivity while blocking TNF-a in
adipose tissue [17].
This study has some limitations, including the lack of
randomization, the use of retrospective recordings, the
inadequate exclusion of other possible causes, and the
use of a high glucose threshold, undermining the clinical
significance of such low levels of glucose. We believe
that more investigations are needed to examine this
complex relationship between TNF-a and glucose
equilibrium.
Physicians using TNF-a inhibitors in the treatment of
various rheumatic and autoimmune diseases should be
aware of the potential for the development of glycemic
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underpublicized. Accordingly, closer monitoring of
blood glucose levels should be rendered. Further rando-
mized controlled studies on the relationship between
TNF-a inhibitors and glycemic control are warranted,
along with more studies examining the possible thera-
peutic role of TNF-a inhibitors in controlling other
autoimmune diseases, such as DM.
Consent
Written informed consent was obtained from the
patients for publication of this case report and any
accompanying images. A copy of the written consent is
available for review by the Editor-in-Chief of this
journal.
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